Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27753673 | 0.80 | FAAH (0.54) | FAAHCNR1CNR2CA2ALDH1A1 | |
| SCHEMBL31470621 | 0.80 | FAAH (0.54) | FAAHCNR1CNR2CA2ALDH1A1 | |
| SCHEMBL27709034 | 0.79 | CA1 (0.46) | FAAHZDHHC7MAPTCA2ACE2 | |
| SCHEMBL27849177 | 0.76 | TSHR (0.50) | FAAHCNR1CNR2ZDHHC7MAPT | |
| SCHEMBL16973568 | 0.75 | ACE2 (0.50) | FAAHZDHHC7MAPTCA2ACE2 | |
| SCHEMBL16795951 | 0.75 | ACE2 (0.50) | FAAHZDHHC7MAPTCA2ACE2 | |
| SCHEMBL18334305 | 0.75 | PRSS1 (0.48) | FAAHZDHHC7MAPTCA2ALDH1A1 | |
| SCHEMBL79493 | 0.75 | PRSS1 (0.48) | FAAHZDHHC7MAPTCA2ALDH1A1 | |
| SCHEMBL18595283 | 0.75 | PRSS1 (0.48) | FAAHZDHHC7MAPTCA2ALDH1A1 | |
| SCHEMBL26312888 | 0.73 | TSHR (0.47) | ZDHHC7MAPTCA2ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | FAAH 2359/4885CNR1 564/4885CNR2 419/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | FAAH 1637/4885CNR1 1081/4885CNR2 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.